Novocure Ltd Stock
Novocure Ltd Stock
Pros and Cons of Novocure Ltd in the next few years
Pros
Cons
Performance of Novocure Ltd vs. its peers
Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
---|---|---|---|---|---|---|---|
Novocure Ltd | 3.070% | 4.053% | -2.114% | -79.652% | -17.268% | -93.443% | - |
Iovance Biotherapeutics Inc. | -1.440% | 2.211% | -16.359% | 119.362% | 39.152% | -60.289% | - |
Sage Therapeutics Inc. | -0.350% | 2.037% | -26.156% | -70.428% | -36.125% | -80.292% | - |
Fibrogen Inc. | -0.330% | -11.959% | -58.142% | -94.914% | 10.000% | -94.708% | - |
News
Results of Novocure’s METIS Phase 3 Clinical Trial for Patients with Brain Metastasis from Non-Small Cell Lung Cancer to be Presented as Late-Breaking Abstract at ASCO 2024
Novocure (NASDAQ: NVCR) today announced the results of the METIS phase 3 clinical trial in brain metastases from non-small cell lung cancer (NSCLC) will be presented at the 2024 American Society of
Novocure Announces 20 Presentations On Tumor Treating Fields, Highlighting Preclinical Effects in Pancreatic Cancer and Immune Effects, at American Association for Cancer Research (AACR) Annual Meeting 2024
Novocure (NASDAQ: NVCR) today announced 20 presentations on Tumor Treating Fields (TTFields) therapy will be delivered at the American Association for Cancer Research (AACR) Annual Meeting 2024, to
Novocure to Report First Quarter 2024 Financial Results
Novocure (NASDAQ: NVCR) announced today that it will report financial results for the first quarter 2024 on Thursday, May 2, 2024, before the U.S. financial markets open. Novocure management will